Search results
Results from the WOW.Com Content Network
In September 2020, Sinovac began Phase I–II trials in China on children and adolescents ages 3–17. [92] In May 2021, Sinovac began Phase IIb trials in China with 500 participants for children and adolescents 3–17 years old. [93] In June 2021, it was announced that the vaccine was safe and immunogenic in this age group. [94]
Offering Sinovac Biotech COVID-19 vaccines to the public in Singapore for the first time since Friday, several private clinics reported overwhelming demand for the Chinese-made shot, despite ...
[31] [32] [33] By April 2021, Sinovac had a production capacity of two billion doses a year [34] and had delivered 600 million total doses. [35] It is currently being manufactured at several facilities in China, [34] Brazil, [36] and Egypt. [37] On 1 June 2021, the World Health Organization (WHO) validated the vaccine for emergency use.
Singapore also received its first shipment of Sinovac Biotech's CoronaVac vaccine, on 22 December 2020. However, the vaccine was not authorised for use by the Health Sciences Authority (HSA). [ 12 ] [ 13 ] On 2 June 2021, MOH approved the Sinovac vaccine for used in private healthcare settings so people, who are not suitable to take the mRNA ...
The World Health Organization (WHO) said on Tuesday it has approved a COVID-19 vaccine made by Sinovac Biotech for emergency use listing, paving the way for a second Chinese shot to be used in ...
Thailand Food and DrugAdministration (FDA) on Monday gave emergency use authorisationfor the COVID-19 vaccine of Sinovac Biotech, paving theway for the country's first coronavirus inoculations.
Indonesia gave Sinovac Biotech's COVID-19 vaccine its first emergency use approval outside China on Monday as the world's fourth most populous country launches nationwide inoculations to stem ...
[132] [133] [134] The EMA released an update on the status of its rolling review of the COVID‑19 Vaccine AstraZeneca in December 2020, after the UK granted a temporary authorization of supply for the vaccine. [135] In November 2020, the EMA published a safety monitoring plan and guidance on risk management planning (RMP) for COVID‑19 ...